NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Tony Mok, Nobuyuki Yamamoto et al.|Journal of Thoracic Oncology|2022Cited by 72